Abbisko Cayman Ltd
HKEX:2256

Watchlist Manager
Abbisko Cayman Ltd Logo
Abbisko Cayman Ltd
HKEX:2256
Watchlist
Price: 4.33 HKD -0.23% Market Closed
Market Cap: 2.9B HKD
Have any thoughts about
Abbisko Cayman Ltd?
Write Note

Operating Margin
Abbisko Cayman Ltd

-4%
Current
-3 747%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-4%
=
Operating Profit
-19.7m
/
Revenue
497.3m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CN
Abbisko Cayman Ltd
HKEX:2256
3B HKD
-4%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
35.8B EUR
-22%
Country CN
Market Cap 3B HKD
Operating Margin
-4%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 310.3B USD
Operating Margin
28%
Country US
Market Cap 141.6B USD
Operating Margin
19%
Country US
Market Cap 115.3B USD
Operating Margin
38%
Country US
Market Cap 102.4B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 77.3B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 35.8B EUR
Operating Margin
-22%
No Stocks Found

Abbisko Cayman Ltd
Glance View

Market Cap
3B HKD
Industry
Biotechnology

Abbisko Cayman Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Intrinsic Value
2.41 HKD
Overvaluation 44%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-4%
=
Operating Profit
-19.7m
/
Revenue
497.3m
What is the Operating Margin of Abbisko Cayman Ltd?

Based on Abbisko Cayman Ltd's most recent financial statements, the company has Operating Margin of -4%.